###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 56 64 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1</italic>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 440 446 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
The amplicon on 8p11.2 is reported to be found in up to 10% of breast carcinomas. It has been demonstrated recently that this amplicon has four separate cores. The second core encompasses important oncogene candidates, including the fibroblast growth factor receptor 1 (FGFR1) gene. Recent studies have demonstrated that specific FGFR1 amplification correlates with gene expression and that FGFR1 activity is required for the survival of a FGFR1 amplified breast cancer cell line.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 132 140 132 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1</italic>
###xml 213 221 213 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
FGFR1 amplification was analysed in tissue microarrays comprising a cohort of 880 unselected breast tumours by means of chromogenic in situ hybridisation using inhouse-generated FGFR1-specific probes. Chromogenic in situ hybridisation signals were counted in a minimum 30 morphologically unequivocal neoplastic cells. Amplification was defined as >5 signals per nucleus in more than 50% of cancer cells or when large gene copy clusters were seen.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 254 260 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 425 431 425 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
FGFR1 amplification was observed in 8.7% of the tumours and was significantly more prevalent in patients >50 years of age and in tumours that lacked HER2 expression. No association was found with other histological parameters. Survival analysis revealed FGFR1 amplification as an independent prognostic factor for overall survival in the whole cohort. Subgroup analysis demonstrated that the independent prognostic impact of FGFR1 amplification was only seen in patients with oestrogen-receptor-positive tumours, where FGFR1 amplification was the strongest independent predictor of poor outcome.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
Given that up to 8.7% of all breast cancers harbour FGFR1 amplification and that this amplification is an independent predictor of overall survival, further studies analysing the FGFR1 as a potential therapeutic target for breast cancer patients are warranted.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1</italic>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 443 449 443 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 667 675 667 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FLJ14299</italic>
###xml 707 712 707 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPFH2</italic>
###xml 728 734 728 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C8orf2</italic>
###xml 800 804 800 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRF2</italic>
###xml 846 855 846 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAB11FIP1</italic>
###xml 858 859 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Amplification of 8p11.2-p12 is reported to be found in up to 10-15% of all breast cancers [1-5]. For a long time it was believed that the fibroblast growth factor receptor 1 (FGFR1) would be the target oncogene of 8p11.2-p12 amplifications [1,2,5,6]. Recent studies, however, have called into question the role of FGFR1 as the 'amplicon driver', given that not all cell lines and breast cancers with 8p11.2-p12 amplification overexpressed the FGFR1 gene and that FGFR1 protein and mRNA expression was much more pervasive than gene amplification [7-9]. Other oncogene candidates for the amplicon on 8p11.2-p12 have been put forward, including zinc finger protein 703 (FLJ14299), SPFH domain family member 2 (SPFH2, also known as C8orf2), subunit of RNA polymerase III transcription initiation factor (BRF2) and RAB11 family interacting protein 1 (RAB11FIP1) [7].
###end p 11
###begin p 12
###xml 28 29 28 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 244 252 244 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FLJ14299</italic>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPFH2</italic>
###xml 305 310 305 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PROSC</italic>
###xml 313 317 313 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRF2</italic>
###xml 323 333 323 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAB11FIP1 </italic>
###xml 385 391 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GOLGA7</italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYST3</italic>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AP2M3</italic>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSM1</italic>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASM</italic>
###xml 738 743 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDHD2</italic>
###xml 805 810 805 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTPAP</italic>
###xml 858 865 858 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WHSC1L1</italic>
###xml 868 872 868 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TM2 </italic>
###xml 876 882 876 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 883 884 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1006 1007 1006 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Gelsi-Boyer and colleagues [3] have demonstrated more recently that the 8p11.2-p12 amplicon is much more complex than previously anticipated and that it comprises at least four independent cores, which can be amplified independently [3]. While FLJ14299, SPFH2, proline synthetase cotranscribed homologue (PROSC), BRF2, and RAB11FIP1 were associated with core A1, golgin subfamily a 7 (GOLGA7) was correlated with A3, and MYST histone acetyltransferase 3 (MYST3) and miR172-resistant version of AP2 (AP2M3) were associated with A4. The genes whose expression correlated with amplification of core A2 included LSM1 homologue, U6 small nuclear RNA associated (LSM1, also known as cancer-associated Sm-like (CASM)), DDHD domain containing 2 (DDHD2), phosphatidic acid phosphatase type 2 domain containing 1B (HTPAP), Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1), TM2 and FGFR1 [3]. Interestingly, amplification of core 2, but not the other cores, was associated with shorter metastasis-free survival [3].
###end p 12
###begin p 13
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 696 705 696 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 762 768 762 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 290 295 <span type="species:ncbi:10090">mouse</span>
FGFR1 gene encodes a tyrosine kinase receptor that is part of the fibroblast growth factor and growth factor receptors family [10-12]. FGFR1 expression has been shown to play pivotal roles in mammary development and breast cancer tumourigenesis [12,13]. Activation of FGFR1 in a transgenic mouse model resulted in increased luminal cell proliferation, activation of mitogen-activated protein kinase and Akt, lateral budding and, eventually, alveolar hyperplasia and invasive lesions [11,12]. In addition, we have recently demonstrated that when core 2 of the 8p11.2-p12 is amplified, the FGFR1 gene shows increased levels of mRNA and protein expression [14]. Furthermore, we have also determined in vitro that FGFR1 signalling is paramount for the survival of a FGFR1 amplified breast cancer cell line [14].
###end p 13
###begin p 14
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 176 184 176 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 518 528 518 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAB11FIP1 </italic>
###xml 532 537 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1</italic>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 457 465 <span type="species:ncbi:9606">patients</span>
The prognostic impact of FGFR1 amplification in breast cancer still remains unclear. In previous studies analysing FGFR1 amplification by means of Southern blot or fluorescent in situ hybridisation, conflicting results were observed: while FGFR1 amplification proved to be associated with positivity for oestrogen receptor (ER) in one study [1], Prentice and colleagues found no association between FGFR1 amplification and clinicopathological parameters or patients' survival [4]. More recently, using probes for both RAB11FIP1 and FGFR1, Letessier and colleagues [15] demonstrated that cases with 8p12 amplification have a significantly shorter metastasis-free survival [15].
###end p 14
###begin p 15
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 270 278 270 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 524 530 524 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 707 713 707 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 777 783 777 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
Chromogenic in situ hybridisation (CISH) is a technique that allows for a concurrent analysis of the gene copy number and morphological features of the cells [16-21]. Although results obtained with CISH show an excellent concordance with those obtained with fluorescent in situ hybridisation [21], CISH has proven useful for high-throughput copy number assessment, given that it can be easily applied to tissue microarrays and the analysis can be performed with a conventional light microscope [16-21]. No studies analysing FGFR1 amplification, as defined by CISH, in a large cohort of breast cancer patients have so far been performed. Using a previously described method [18], inhouse probes specific for FGFR1 were generated and we set out to characterise the prevalence of FGFR1 amplification in a large community-based cohort of breast cancers and its correlations with traditional clinicopathological features, immunohistochemical markers, and disease-free and overall survival.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Tissue microarrays
###end title 17
###begin p 18
###xml 1039 1041 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1157 1158 1153 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1237 1239 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1305 1307 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1358 1360 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 605 612 <span type="species:ncbi:9606">Patient</span>
###xml 730 738 <span type="species:ncbi:9606">Patients</span>
###xml 1124 1132 <span type="species:ncbi:9606">patients</span>
The tissue microarrays comprised a cohort of 880 unselected breast tumours from patients presenting between 1986 and 1998 entered into the Nottingham Tenovus Primary Breast Carcinoma Series (447 invasive ductal carcinomas of no special type, 183 tubular mixed carcinomas, 25 medullary carcinomas, 84 lobular carcinomas, 28 tubular carcinomas, eight mucinous carcinomas, six cribriform carcinomas, four papillary carcinomas, 29 mixed no special type and lobular carcinomas, 23 mixed no special type and special-type carcinomas, and six miscellaneous tumours - histological type not available in 37 cases). Patient management was based on tumour characteristics by the Nottingham Prognostic Index (NPI) and hormone receptor status. Patients with an NPI score </=3.4 received no adjuvant therapy, and those with a NPI score >3.4 received tamoxifen if they were ER-positive (+/- Zoladex if premenopausal) or received classical cyclophosphamide, methotrexate and 5-fluorouracil if they were ER-negative and fit enough to tolerate chemotherapy [22]. Full details of the characterisation of the tissue microarray and the cohort of patients are summarised in Table 1. Tumours were graded according to a modified Bloom-Richardson scoring system [23] and size was categorised according to the TNM staging criteria [24]. The NPI was calculated as previously described [25].
###end p 18
###begin p 19
###xml 300 307 300 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Survival data including the survival time and the disease-free interval were maintained on a prospective basis. Disease-free survival was defined as the interval (in months) from the date of the primary surgical treatment to the first locoregional (including invasive malignancy and ductal carcinoma in situ) or distant recurrence. Overall survival was taken as the time (in months) from the date of the primary surgical treatment to the time of death from breast cancer. The immunohistochemical methods and the results on ER, progesterone receptor, cytokeratin (CK) 7/8, CK 18, CK 19, CK 5/6, CK 14, HER2 and epidermal growth factor receptor have been previously described [26,27].
###end p 19
###begin p 20
This study was approved by the Nottingham Research Ethics Committee 2 under the title 'Development of a molecular genetic classification of breast cancer'.
###end p 20
###begin title 21
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
Chromogenic in situ hybridisation
###end title 21
###begin p 22
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 185 187 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 384 390 383 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 402 409 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WHSC1L1</italic>
###xml 796 802 789 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
CISH for FGFR1 gene amplification was performed on 2-mum-thick tissue microarray sections mounted on polylysine-coated slides, using an inhouse-generated probe as previously described [18]. This probe comprises three bacterial artificial chromosome contigs (RP11-350N15, RP11-148D21 and RP11-359P11), which map to the region 38.3-38.6 Mb on chromosome 8p12-p11.23 and encompasses the FGFR1 and part of WHSC1L1. Heat pretreatment of deparaffinised sections consisted of incubation for 15 minutes at 98degreesC in CISH pretreatment buffer (SPOT-light tissue pretreatment kit; Zymed (South San Francisco, CA, USA) and digestion with pepsin for 5.5 minutes at room temperature according to the manufacturer's instructions. Slides were hybridised and developed as previously described. An appropriate FGFR1 gene-amplified breast carcinoma control was included in the slide run.
###end p 22
###begin p 23
###xml 309 315 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
CISH experiments were analysed by two of the authors (SEE and ARG) on a multiheaded microscope. Only unequivocal signals were counted. Signals were evaluated at 400 x magnification and 630 x magnification, and 30 morphologically unequivocal neoplastic cells in each core were assessed for the presence of the FGFR1 gene signals. Amplification was defined as those cases where >50% of the neoplastic cells harboured either >5 copies of the gene or large gene clusters. CISH analysis was performed with observers blinded to clinicopathological parameters, patients' survival and results of the immunohistochemical analysis.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 455 462 <span type="species:ncbi:9606">patient</span>
Statistical analysis was performed using SPSS 13.0 statistical software (SPSS INC., Chicago, IL, USA). Median follow-up was defined as the median follow-up for those patients still alive and disease free at the latest hospital visit. Cutoff values for the different biomarkers included in this study were chosen before statistical analysis. Standard cutoff values were used for established prognostic factors and were the same as for previously published patient series [27]. All factors were used as dichotomous covariates in the statistical analysis with the exception of grade and the NPI, which were categorised into three groups.
###end p 25
###begin p 26
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 177 179 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 333 339 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
The associations between the FGFR1 amplification and clinicopathological parameters were evaluated by the chi-square test. Confidence intervals of 95% were adopted. A two-sided P value <0.05 was considered statistically significant. Survival curves were calculated by the Kaplan-Meier method. Differences in survival on the basis of FGFR1 amplification were estimated using the log-rank test. Multivariate Cox regression analysis was used to evaluate any independent prognostic effect of the variable on disease-free survival and the overall survival, which was adjusted by such well-known prognostic factors as tumour grade, lymph node stage, tumour size, and ER status.
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
After excluding the uninformative tissue microarray cores, results on FGFR1 amplification were available for 496 tumours. Forty-three tumours (8.7%) showed either >5 signals or large gene clusters in >50% of neoplastic cells (Figure 1).
###end p 28
###begin p 29
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 851 853 849 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 883 885 881 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 405 413 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
###xml 967 975 <span type="species:ncbi:9606">patients</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
Complete clinical follow-up information was available for 478 patients for whom FGFR1 CISH results were optimal. The median follow-up period was 58 months (range 1-192 months). During this period, a total of 73 (14.7%) patients died from breast cancer. Of all cases, 116 (24.3%) cases were grade 1, 141 (29.5%) cases were grade 2, and 221 (46.2%) were grade 3. From the available data, 153 (32.2%) of the patients had lymph-node-positive disease, 130 (27.8%) had positive vascular invasion, and 311 (65.1%) had tumour size >/=1.5 cm. Recurrence occurred in 147 cases (30.8%), and distant metastases developed in 84 cases (17.6%). A total of 149/496 (30%) patients received tamoxifen, 5/496 (1%) received tamoxifen and Zoladex, and 309/496 (62.3%) received no endocrine treatment. There was no significant difference between the disease-free interval (P = 0.761) or overall survival (P = 0.225) between those patients that received hormone therapy compared with those patients that did not. A total of 48/496 (9.7%) patients received chemotherapy.
###end p 29
###begin p 30
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 230 232 230 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 275 277 275 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Table 2 summarises the associations between FGFR1 gene amplification and key prognostic and outcome parameters. In brief, patients with positive FGFR1 amplification were significantly more likely to be older than 50 years of age (P < 0.05) and to develop distant metastasis (P < 0.05). FGFR1 amplification showed an inverse correlation with HER2 overexpression. A trend for lack of progesterone receptor expression and negativity for basal markers, as defined by Abd El-Rehim and colleagues [27], was also observed. No associations were found between FGFR1 amplification and the grade, lymph-node stage, NPI, expression of ER, low-molecular-weight cytokeratins (CK 7/8, CK 8 and CK 19) or high-molecular-weight cytokeratins (CK 5/6 and CK 14) or basal-like phenotype as defined by Nielsen and colleagues [28] (that is, ER-negative and HER2-negative, CK 5/6 and/or epidermal growth factor receptor-positive).
###end p 30
###begin p 31
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 115 117 115 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 232 234 232 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 554 556 554 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Kaplan-Meier survival analysis revealed an association between FGFR1 amplification and a shorter overall survival (P = 0.01, log-rank test) (Figure 2a). A trend for a shorter disease-free survival and FGFR1 amplification was found (P < 0.07, log-rank test) (Figure 2b). On multivariate Cox hazard analysis adjusted for tumour grade, size and lymph node status, for ER status, and for FGFR1 amplification, it was found that the FGFR1 amplification was a significant predictor of poor overall survival independent of the other known prognostic parameters (P < 0.04) (Table 3).
###end p 31
###begin p 32
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c,d</xref>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e,f</xref>
###xml 339 345 339 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 549 555 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 724 726 724 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 815 821 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 922 928 922 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">Patients</span>
###xml 958 966 <span type="species:ncbi:9606">patients</span>
Subgroup analysis revealed that FGFR1 amplification was an independent prognostic factor for disease-free survival and overall survival only in ER-positive tumours (Figure 2c,d and Table 4). The association between FGFR1 amplification and poor outcome was maintained in the group of patients that received endocrine therapy (Figure 2e,f). FGFR1 amplification in ER-positive disease was the strongest independent risk factor for poor disease-free survival and overall survival, with a greater hazard ratio than high histological grade. Patients with FGFR1 amplification in the ER-positive group were significantly more likely to develop distant metastases and were associated with a lack of progesterone receptor expression (P < 0.05) (Table 5). In the cohort of ER-positive tumours, no further associations between FGFR1 amplification and other clinicopathological parameters were found. No associations were seen between FGFR1 amplification and survival of patients with ER-negative breast cancers.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 208 216 208 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
In recent years it has been demonstrated that CISH is a useful technique to determine gene copy numbers and gene amplification on formalin-fixed, paraffin-embedded tissue sections [16-21]. Unlike fluorescent in situ hybridisation, CISH allows a direct comparison between morphological features of neoplastic cells and the presence of gene amplification [16-21]. Furthermore, CISH analysis is relatively quick; in the present study, the whole analysis of FGFR1 amplification in a cohort of 880 patients took 2 weeks and, although only one tissue microarray core per tumour was analysed, 56% cases rendered optimal results.
###end p 34
###begin p 35
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 289 297 289 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 351 357 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 468 474 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 619 625 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 1013 1019 1013 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 1076 1078 1076 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
We demonstrate in the present study that FGFR1 amplification is found in 8.7% of breast cancers, which is in agreement with previous studies [1-4,29]. Unlike previous studies where FGFR1 amplification was determined by Southern blot analysis [1], our results and those obtained with other in situ methods [3,4,15] did not show any correlation between FGFR1 amplification and low histological grade or positivity for ER. On the other hand, our results demonstrate that FGFR1 amplification is an independent predictor of poor outcome, especially for patients with ER-positive breast cancers. Interestingly, the impact of FGFR1 amplification was stronger on overall survival than disease-free survival (that is, higher hazard ratios on multivariate analysis). This may stem from the fact that locoregional recurrences were included as events for disease-free survival analysis, and that overall survival considered only breast-cancer-related deaths as events. Alternatively, this may reflect the association between FGFR1 amplification and the development of distant metastasis (P = 0.05) or a shorter survival after the first distant recurrence event.
###end p 35
###begin p 36
###xml 11 13 11 13 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 27 28 27 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 188 194 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 264 270 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 501 507 501 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
Our group [14] and others [3] have demonstrated that when FGFR1 is specifically amplified (that is, amplification of core A2 of the 8p11.2-p12 amplicon) it is also overexpressed, and that FGFR1 signalling is important for the survival of a cell line that harbours FGFR1 amplification and high-level gene expression [14,30]. Taken together, these results suggest that, in a significant proportion of cases with core A2 amplification, FGFR1 may be the actual amplicon driver [6]. We could not correlate FGFR1 amplification with expression in this study, as it was not possible to optimise antibodies for FGFR1 immunohistochemical analysis on tissue microarrays due to the highly fixation-dependent nature of the commercially available antibodies (data not shown).
###end p 36
###begin p 37
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 165 174 165 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 178 186 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 463 466 463 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR</italic>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 727 734 727 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNF198 </italic>
###xml 738 744 738 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 880 886 880 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZNF198</italic>
###xml 887 892 887 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1</italic>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1203 1209 1203 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 1224 1226 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
The FGFR1 gene encodes a tyrosine kinase receptor that has been shown to play an important role in mammary gland development [12,13,31]. Previous studies have shown in vitro and in vivo that FGFR1 overexpression has oncogenic properties [10,12-14,31]. Furthermore, FGFR1 has been implicated in the tumourigenesis of haematological malignancies, where it is frequently involved in balanced chromosomal translocations, including cases of chronic myeloid leukaemia (BCR-FGFR1 fusion) and the 8p11 myeloproliferative syndrome/stem cell leukaemia-lymphoma syndrome, which is characterised by myeloid hyperplasia and non-Hodgkin's lymphoma with chromosomal translocations fusing several genes, the most common being a fusion between ZNF198 and FGFR1 [32]. In preclinical models, the PKC412 tyrosine kinase inhibitor has been shown to successfully inhibit the growth of proliferation of ZNF198-FGFR1-transformed Ba/F3 cells and to prolong the survival of animals with a ZNF198-FGFR1-induced stem cell leukaemia-lymphoma syndrome [33]. Targeting FGFR1 signalling with RNA interference or with the SU5402 FGFR1 tyrosine kinase inhibitor has been shown to decrease cell survival in a breast cancer cell line with FGFR1 amplification [14].
###end p 37
###begin title 38
Conclusion
###end title 38
###begin p 39
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 429 435 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 661 667 661 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
Taken together, our results demonstrate that FGFR1 amplification is found in 8.7% of breast cancers and is an independent predictor of outcome. Although large studies correlating FGFR1 amplification with mRNA and protein expression are still needed, the functional data demonstrating that FGFR1 signalling is required for the survival of breast cancer cells harbouring FGFR1 amplification [14], the relatively high prevalence of FGFR1 amplification in breast cancer and the independent prognostic information provided by FGFR1 amplification status support the idea that this gene may be a useful therapeutic target for a subgroup of breast cancer patients with FGFR1 gene amplification [14].
###end p 39
###begin title 40
Abbreviations
###end title 40
###begin p 41
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
CISH = chromogenic in situ hybridisation; CK = cytokeratin; ER = oestrogen receptor; FGFR1 = fibroblast growth factor receptor 1; NPI = Nottingham Prognostic Index.
###end p 41
###begin title 42
Competing interests
###end title 42
###begin p 43
The authors declare that they have no competing interests.
###end p 43
###begin title 44
Authors' contributions
###end title 44
###begin p 45
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 578 583 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1</italic>
SEE and ARG analysed the CISH experiments, performed in part the statistical analysis and helped to draft the manuscript. MBKL performed the laboratory work for FGFR1 inhouse probe generation and hybridisation to tissue microarrays. NCT participated in the study design, the interpretation of the results and statistical analysis. MJG supervised and reviewed the statistical analysis. DP participated in the interpretation of the results. IOE participated in the study design, data analysis and helped to draft the manuscript. JSR-F conceived the study, designed the probes for FGFR1, supervised the statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.
###end p 45
###begin title 46
Acknowledgements
###end title 46
###begin p 47
This study was supported in part by Breakthrough Breast Cancer. The authors are grateful to Professor Alan Ashworth for his invaluable comments.
###end p 47
###begin article-title 48
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups
###end article-title 48
###begin article-title 49
Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations
###end article-title 49
###begin article-title 50
Comprehensive profiling of 8p11-12 amplification in breast cancer
###end article-title 50
###begin article-title 51
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis
###end article-title 51
###begin article-title 52
FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers
###end article-title 52
###begin article-title 53
Differential expression assay of chromosome arm 8p genes identifies frizzled-related (FRP1/FRZB) and fibroblast growth factor receptor 1 (FGFR1) as candidate breast cancer genes
###end article-title 53
###begin article-title 54
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes
###end article-title 54
###begin article-title 55
###xml 59 64 <span type="species:ncbi:9606">human</span>
Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines
###end article-title 55
###begin article-title 56
Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines
###end article-title 56
###begin article-title 57
Cellular signaling by fibroblast growth factor receptors
###end article-title 57
###begin article-title 58
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland
###end article-title 58
###begin article-title 59
Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model
###end article-title 59
###begin article-title 60
A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor
###end article-title 60
###begin article-title 61
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
###end article-title 61
###begin article-title 62
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
###end article-title 62
###begin article-title 63
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
###end article-title 63
###begin article-title 64
###xml 8 10 8 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis
###end article-title 64
###begin article-title 65
###xml 129 136 129 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization
###end article-title 65
###begin article-title 66
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
###end article-title 66
###begin article-title 67
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
Chromogenic in situ hybridization in tumor pathology
###end article-title 67
###begin article-title 68
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization
###end article-title 68
###begin article-title 69
Loss of CD59 expression in breast tumours correlates with poor survival
###end article-title 69
###begin article-title 70
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
###end article-title 70
###begin article-title 71
Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual
###end article-title 71
###begin article-title 72
The Nottingham Prognostic Index in primary breast cancer
###end article-title 72
###begin article-title 73
High throughput protein expression analysis using tissue microarray technology of a large well characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
###end article-title 73
###begin article-title 74
###xml 48 53 <span type="species:ncbi:9606">human</span>
Expression of luminal and basal cytokeratins in human breast carcinoma
###end article-title 74
###begin article-title 75
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
###end article-title 75
###begin article-title 76
CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei
###end article-title 76
###begin article-title 77
MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands
###end article-title 77
###begin article-title 78
Roles of FGF receptors in mammalian development and congenital diseases
###end article-title 78
###begin article-title 79
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations
###end article-title 79
###begin article-title 80
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder
###end article-title 80
###begin title 81
Figures and Tables
###end title 81
###begin p 82
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 43 47 43 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 141 145 141 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 218 222 218 222 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 322 326 322 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 326 332 326 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
FGFR1 gene amplification in breast cancer. (a) Grade 3 invasive ductal carcinoma (haematoxylin and eosin; original magnification x 200) with (b) one or two copies of FGFR1 (original magnification x 400; inset: x 630). (c) Grade 3 invasive ductal carcinoma (haematoxylin and eosin; original magnification x 200) harbouring (d) FGFR1 gene amplification (original magnification x 400; inset: x 630).
###end p 82
###begin p 83
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
###xml 135 139 135 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 176 180 176 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 212 216 212 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 274 278 274 278 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 331 335 331 335 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 428 432 428 432 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
Univariate analysis of the prognostic impact of FGFR1 gene amplification overexpression on disease-free survival and overall survival. (a) Whole cohort, disease-free survival. (b) Whole cohort, overall survival. (c) Oestrogen-receptor-positive cases, disease-free survival. (d) Oestrogen-receptor-positive cases, overall survival. (e) Oestrogen-receptor-positive patients that received endocrine therapy, disease-free survival. (f) Oestrogen-receptor-positive patients that received endocrine therapy, overall survival.
###end p 83
###begin p 84
###xml 93 100 <span type="species:ncbi:9606">patient</span>
Frequencies and percentages of tumour grades, size, lymph node stage, distant metastasis and patient age in the tissue microarrays
###end p 84
###begin p 85
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
Correlation between FGFR1 gene amplification and the clinicopathological variables
###end p 85
###begin p 86
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
Cox proportional hazards analysis for predictors of overall survival: effects of tumour grade, size, lymph node stage, oestrogen receptor status and FGFR1 amplification
###end p 86
###begin p 87
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aFitted as a linear term; that is, an increase in risk for change in grade of one unit.
###end p 87
###begin p 88
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bCompared with tumour size <1.5 cm.
###end p 88
###begin p 89
Cox proportional hazards analysis for predictors of disease-free and overall survival: effects of tumour grade, size, lymph node stage, oestrogen receptor (ER) status and FGFR1 status in ER-positive and ER-negative tumours
###end p 89
###begin p 90
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aFitted as a linear term; that is, an increase in risk for change in grade of one unit.
###end p 90
###begin p 91
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bCompared with tumour size <1.5 cm.
###end p 91
###begin p 92
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR1 </italic>
Correlation between FGFR1 gene amplification and the clinicopathological variables in the oestrogen-receptor-positive group
###end p 92

